Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Simultaneous determination of rifampicin, isoniazid, pyrazinamide and ethambutol in fixed-dose combination antituberculosis pharmaceutical formulations: a review

Full text
Author(s):
Oliveira, M. A. L. [1] ; Chellini, P. R. [2] ; Amorim, T. L. [1]
Total Authors: 3
Affiliation:
[1] Univ Fed Juiz de Fora, Chem Dept, BR-36036330 Juiz De Fora, MG - Brazil
[2] Univ Fed Juiz de Fora, Fac Farm, BR-36036330 Juiz De Fora, MG - Brazil
Total Affiliations: 2
Document type: Review article
Source: ANALYTICAL METHODS; v. 10, n. 10, p. 1103-1116, MAR 14 2018.
Web of Science Citations: 2
Abstract

According to the World Health Organization, rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride are the first-line drugs used to treat tuberculosis - an infectious disease caused by Mycobacterium tuberculosis. Since 2010, tuberculosis has been treated with a fixed-dose combination containing the four drugs in only one tablet, called 4-FDC, which has simplified the treatment, minimized prescription errors and increased patients' adherence to their treatment regime. Within this context, the present review aims to show the evolution of different analytical methods that have been applied to simultaneous 4-FDC content determination in pharmaceutical formulations, such as high performance liquid chromatography, ultrahigh performance liquid chromatography, thin layer chromatography and capillary electrophoresis as separation techniques and molecular spectroscopic techniques associated with chemometric approaches, such as UV, Raman, Fourier transform infrared and near infrared. (AU)

FAPESP's process: 14/50867-3 - INCT 2014: National Institute of Science and Technology in Bioanalysis
Grantee:Marco Aurelio Zezzi Arruda
Support Opportunities: Research Projects - Thematic Grants